Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. The NDA-filing process is ongoing and expected to be completed by the end of February 2008.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal th
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... La Jolla, Calif. (PRWEB) September 30, 2014 ... (NIH) announced the initial round of grants for ... Initiative, an undertaking that aims to develop and ... neuro circuit functions of the human brain. This ... funding for fiscal year 2014 was allocated to ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Award ... SoundConnect announces four new-hosted collaboration bundles that ... deliver high quality conferencing experiences for low, flat ... to choose from, businesses have optimized solutions to ... solutions include audio only minutes (1K, 5K, ...
(Date:10/1/2014)... The U.S. Department of Labor has awarded a ... part of the Trade Adjustment Assistance Community College and ... the Department of Labor and Department of Education. , ... Perez and Secretary of Education Arne Duncan announced the ... nearly 270 colleges across the country. , The ...
(Date:9/30/2014)... This news release is available in German . ... photonic crystal around several quantum dots in a semiconductor layer. ... a consequence of atomic processes. If a short laser pulse ... modified and the quantum dot experiences a change in the ... slow down the emission of light by the dot. As ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3SoundConnect Launches New Audio, Web and Video Bundles 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Ultrafast remote switching of light emission 2
... WELWYN GARDEN CITY, England, October 12 , ... Potential Fees and Milestones Plus,Royalties , ... (GPCR) targets, announced today that it has,entered into an option ... its proprietary StaR(TM) technology to generate novel,drug leads against a ...
... For U.S. Media Only , ... - 68 percent of women living with rheumatoid arthritis look ... - Almost 60 percent of women in the U.S. living with rheumatoid arthritis,find ... role in 25 percent of divorces amongst,women with the disease , ...
... variety of fields has analysed the effects of human ... Park. Results show that the lagoons are in the ... underground water for the Matalascaas tourist resort (Huelva). Moreover, ... aggravating the situation. Botanists, limnologists and climatologists from ...
Cached Biology Technology:Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target 2Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target 3New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations 2New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations 3Huelva is swallowing up coastal lagoons in Doñana 2
(Date:10/1/2014)... 1, 2014 Novel detection ... science field  The life science field ... over the years. Some are shooting stars and ... a novel detection technology that has raised much ... this technology is becoming commercially available. With their ...
(Date:9/30/2014)... the environmental effects of moorland burning is published today ... with the aim of relieving tensions on both sides ... EMBER (Effects of Moorland Burning on the Ecohydrology of ... moorland, which is practised predominantly to support red grouse ... peat hydrology, peat chemistry and physical properties, river water ...
(Date:9/30/2014)... conducted by the Ocean Health Index rates the ... overall health. In addition, for the first time, ... ocean regions beyond national jurisdiction (high-seas areas) ... safeguarding biodiversity and providing sustainable food sources. , ... a partnership led by scientists from UC Santa ...
Breaking Biology News(10 mins):First-of-a-kind Solution for Utilizing Photon Upconversion 2Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3
... Strasbourg 18/04/12 - Technology has transformed the way humans interact ... big ideas that will drive growth in marine and maritime ... and policy will gather at the 3rd Marine Board Forum ... Marine Board has convened this flagship event on the understanding ...
... ecologist and entomologist at the University of Guam has just ... weed Mikania micrantha . The mile-a-minute vine is ... Pacific. Mikania,s native range is the tropical and subtropical areas ... on the top ten list of important weeds of Pacific ...
... results presented at 3rd European Lung Cancer Conference in ... the diagnosis and treatment of malignant pleural mesothelioma, an ... caused by asbestos exposure. Micro RNAs speed ... molecule that is more abundant in the blood of ...
Cached Biology News:New technologies for a blue future 2Weeding out invasive species with classical biological control 2Promising developments in early diagnosis and treatment of mesothelioma 2Promising developments in early diagnosis and treatment of mesothelioma 3Promising developments in early diagnosis and treatment of mesothelioma 4
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
...
... High Protein Concentration Basement Membrane Extract ... in in vivo applications where higher ... increased gel strength, and elevated levels ... the advantage of lot-to-lot consistency and ...
Biology Products: